| ||
| ||
| ||
| Immunomedics Reports Final Survival Data With Yttrium-90-Labeled Clivatuzumab ... GlobeNewsWire (press release) Despite recent advances in combination chemotherapy of advanced pancreatic cancer, minimal survival improvement has been achieved. In our first clinical trial, 90 Y-clivatuzumab tetraxetan was evaluated as a single agent and administered in a single ... See all stories on this topic » | ||
| ||
| ASCO: Platinum Chemo Equivalence Questioned MedPage Today The limited evidence from lung cancer and other studies hinted that cisplatin may be a slightly better or more active drug, Isakoff told MedPage Today during his presentation here at the American Society of Clinical Oncology meeting. ... See all stories on this topic » | ||
| Attendees at Malignant Pleural Mesothelioma Seminar Agree to Spare the Lung MesotheliomaHelp.net (blog) During the first scientific seminar dedicated to discussing cancer treatments focused on preserving malignant pleural mesothelioma victims' lungs, the attendees came to unanimous agreement that the lung-sparing pleurectomy/decortication (P/D) is the ... See all stories on this topic » | ||
| Achieved primary endpoint of study with 81% progression free survival rate at ... PipelineReview.com (press release) ... non-small cell lung, malignant melanoma, pancreatic and gastric. ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) is indicated for the treatment of breast cancer after failure of combination ... See all stories on this topic » |
| ||
| Lung cancer pill may double survival - msnbc.com Black News Junkie ... Lung cancer pill may double survival - msnbc.com - BlackNews Junkie: All the Black news a Black news Junkie can handle. Black political news, Black entertainment News, Black sports News. Black News Junkie - All the news... | ||
| A few preliminary lung cancer updates from ASCO « LUNGevity Foundation By Dr West Later in the meeting, Dr. Alice Shaw from Massachusetts General Hospital also provided a comparison of the very favorable survival on the patients with an ALK rearrangement who received crizotinib to the far inferior results of ALK ... Regardless, I expect that Roche/Genetech will use these results to file for an FDA indication for first line treatment with Tarceva for EGFR mutation positive patients with an EGFR mutation, which is also what most lung cancer experts agree ... LUNGevity Foundation |
| ||
| Study: Pfizer lung cancer pill may double survival - Yahoo! Finance TRENTON, N.J. (AP) -- A much-anticipated drug for advanced lung cancer from Pfizer Inc. appears to double survival over standard drugs against tumors with ... biz.yahoo.com/ap/110605/us_pfizer_lung_cancer.html?.v=3 | ||
| Drug may double survival for some lung cancer patients | Dallas ... Dallasnews.com is the official website for The Dallas Morning News newspaper. This page contains Dallas-Fort Worth cancer news and advice. www.dallasnews.com/.../20110606-drug-may-double-survival... | ||
| Study: Pfizer lung cancer pill may double survival Study: Pfizer lung cancer pill may double survival. published about 11 hours ago . (06-05) 08:45 PDT Trenton, N.J. (AP) -- New research shows a promising ... www.newsonfeeds.com/.../Study:%20Pfizer%20lung%20cance... |
Tip: Use a plus sign (+) to match a term in your query exactly as is. Learn more.
Remove this alert.
Create another alert.
Manage your alerts.
No comments:
Post a Comment